Curating Suffering: The Challenges of Mobilising Holocaust Histories, Narratives and Artifacts

With the upsurge in public interest in truth and accessibility to historically suppressed narratives surrounding human atrocities, the research done by archaeologists has taken on a new authority in these discussions as being a tangible link to victims, perpetrators and context. With this comes a return of the common debate amongst researchers, how best to present and represent their work to the public ensuring it is accessible, accurate and interesting. When it comes to knowledge mobilization of sensitive but important events, the Holocaust makes an interesting and relevant case study as debates surrounding its teaching and presentation have been continuous over the last half-century. Current trends favour an upfront and personal approach balancing access with empathy when presenting its narrative. This review of current writings on Holocaust archaeology and museum curation will examine these current practices, their implications, and how artifact collection and presentation affect the interpretation of both the objects and the experience of Holocaust victims. Debates surrounding ownership, narrative viewpoint, practice, comparison, inclusion, assumption, subjectivity and sensitivity will all be discussed, with a final discussion of the importance of ambivalence in the manner Holocaust artifacts are presented to allow for an authentic, respectful but challenging experience to engage with visitors and teach both fact and empathy for an impactful presentation of human atrocity

Focal plane array IR imaging at the Australian Synchrotron

© 2018 A Focal Plane Array FTIR microscope has successfully been coupled to the IRM beamline at the Australian Synchrotron, following the method pioneered at previous beamlines at the SRC and NSLS I synchrotrons, whereby a wide aperture of synchrotron light is split into multiple beams and spatially reconfigured to match the entrance aperture of the FTIR instrumentation. Imaging performance has been assessed using a selection of polymer and biological samples, providing diffraction-limited sub-cellular lateral resolution in the biological materials. We have demonstrated that improved collection times at high lateral resolution are possible, when compared with single element point-mapping microspectroscopy, though this is achieved with a trade off in spectral noise. Future improvements in the use of an FPA detector at the Australian Synchrotron are proposed, including removal of coherent interference and installation of a dedicated beam extraction port for FPA microspectroscopy

Management of coronary disease in patients with advanced kidney disease

BACKGROUND Clinical trials that have assessed the effect of revascularization in patients with stable coronary disease have routinely excluded those with advanced chronic kidney disease. METHODS We randomly assigned 777 patients with advanced kidney disease and moderate or severe ischemia on stress testing to be treated with an initial invasive strategy consisting of coronary angiography and revascularization (if appropriate) added to medical therapy or an initial conservative strategy consisting of medical therapy alone and angiography reserved for those in whom medical therapy had failed. The primary outcome was a composite of death or nonfatal myocardial infarction. A key secondary outcome was a composite of death, nonfatal myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. RESULTS At a median follow-up of 2.2 years, a primary outcome event had occurred in 123 patients in the invasive-strategy group and in 129 patients in the conservative-strategy group (estimated 3-year event rate, 36.4% vs. 36.7%; adjusted hazard ratio, 1.01; 95% confidence interval [CI], 0.79 to 1.29; P=0.95). Results for the key secondary outcome were similar (38.5% vs. 39.7%; hazard ratio, 1.01; 95% CI, 0.79 to 1.29). The invasive strategy was associated with a higher incidence of stroke than the conservative strategy (hazard ratio, 3.76; 95% CI, 1.52 to 9.32; P=0.004) and with a higher incidence of death or initiation of dialysis (hazard ratio, 1.48; 95% CI, 1.04 to 2.11; P=0.03). CONCLUSIONS Among patients with stable coronary disease, advanced chronic kidney disease, and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of death or nonfatal myocardial infarction

Health status after invasive or conservative care in coronary and advanced kidney disease

BACKGROUND In the ISCHEMIA-CKD trial, the primary analysis showed no significant difference in the risk of death or myocardial infarction with initial angiography and revascularization plus guideline-based medical therapy (invasive strategy) as compared with guideline-based medical therapy alone (conservative strategy) in participants with stable ischemic heart disease, moderate or severe ischemia, and advanced chronic kidney disease (an estimated glomerular filtration rate of <30 ml per minute per 1.73 m2 or receipt of dialysis). A secondary objective of the trial was to assess angina-related health status. METHODS We assessed health status with the Seattle Angina Questionnaire (SAQ) before randomization and at 1.5, 3, and 6 months and every 6 months thereafter. The primary outcome of this analysis was the SAQ Summary score (ranging from 0 to 100, with higher scores indicating less frequent angina and better function and quality of life). Mixed-effects cumulative probability models within a Bayesian framework were used to estimate the treatment effect with the invasive strategy. RESULTS Health status was assessed in 705 of 777 participants. Nearly half the participants (49%) had had no angina during the month before randomization. At 3 months, the estimated mean difference between the invasive-strategy group and the conservative-strategy group in the SAQ Summary score was 2.1 points (95% credible interval, 120.4 to 4.6), a result that favored the invasive strategy. The mean difference in score at 3 months was largest among participants with daily or weekly angina at baseline (10.1 points; 95% credible interval, 0.0 to 19.9), smaller among those with monthly angina at baseline (2.2 points; 95% credible interval, 122.0 to 6.2), and nearly absent among those without angina at baseline (0.6 points; 95% credible interval, 121.9 to 3.3). By 6 months, the between-group difference in the overall trial population was attenuated (0.5 points; 95% credible interval, 122.2 to 3.4). CONCLUSIONS Participants with stable ischemic heart disease, moderate or severe ischemia, and advanced chronic kidney disease did not have substantial or sustained benefits with regard to angina-related health status with an initially invasive strategy as compared with a conservative strategy